FDA Will Pursue Longer Follow-Up For Pediatric Studies, Murphy Says
Executive Summary
FDA plans to require longer follow-up for pediatric studies, CDER Associate Director of Pediatrics Dianne Murphy, MD, told the FDA Anti-Infective Drugs Advisory Committee/Pediatric Subcommittee April 23.
You may also be interested in...
PEG-Intron/Ribavirin Pediatric Responder Studies Address Safety Concerns
PEG-Intron/ribavirin combination studies in children with hepatitis C should consider enrolling only early responders to therapy to minimize adverse events, committee member Robert Fink, MD, Children's National Medical Center, suggested at an April 23 meeting of FDA's Anti-Infective Drugs Advisory Committee/Pediatric Subcommittee.
PEG-Intron/Ribavirin Pediatric Responder Studies Address Safety Concerns
PEG-Intron/ribavirin combination studies in children with hepatitis C should consider enrolling only early responders to therapy to minimize adverse events, committee member Robert Fink, MD, Children's National Medical Center, suggested at an April 23 meeting of FDA's Anti-Infective Drugs Advisory Committee/Pediatric Subcommittee.
Postmarketing Study Status Will Be Defined By Trial Making Least Progress
The overall status of a company's postmarketing commitment for a product will be defined by the study which has made the least progress, an FDA draft guidance states.